
Joe Wylie
COMING ON top of the $153m acquisition of Aegerion as recently as September 2019, Amryt Pharma’s current $375m merger with Chiasma represents another major step for the company. As Amryt lost $106m last year, investors will be watching closely to see how CEO Joe Wiley performs and whether he really can deliver on the $1bn... Read more »